The purpose of this study is to see if an investigational twice a year injectable medication can help reduce the risk of getting HIV from sharing needles for drug use.
Study Product
A Phase 2, Open-Label, Multicenter, Randomized Study to Evaluate the Pharmacokinetics and Safety of Twice Yearly Long-Acting Subcutaneous Lenacapavir for Pre-Exposure Prophylaxis in People Who Inject Drugs.
Eligibility
You are at least 18 years old
You are a person who injects drugs and have shared injection supplies in the past month